Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $32 and keeps a Sell rating on the shares. The firm updated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback